ArticleInternational journal of peptide research and therapeutics2006
Characterization of Angiotensin Converting Enzyme-2 (ACE2) in Human Urine.
Article in International journal of peptide research and therapeutics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review.Archives of virology · 2024Review
- COVID-19 infection and severe clinical outcomes in patients with kidney disease by vaccination status: a nationwide cohort study in Korea.Epidemiology and health · 2024Article
- Urinary angiotensin-converting enzyme 2 and its activity in cats with chronic kidney disease.Frontiers in veterinary science · 2024Article
- Association between soluble angiotensin-converting enzyme 2 in saliva and SARS-CoV-2 infection: a cross-sectional study.Scientific reports · 2023Article
- Determination of soluble angiotensin-converting enzyme 2 in saliva samples and its association with nicotine.Environmental research · 2023Article
- Plasma ACE2 species are differentially altered in COVID-19 patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Article
- Regulated Intramembrane Proteolysis of ACE2: A Potential Mechanism Contributing to COVID-19 Pathogenesis?Frontiers in immunology · 2021Review
- Reduced urinary levels of angiotensin-converting enzyme 2 activity predict acute kidney injury in critically ill patients.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2020Article
- Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.Reviews in medical virology · 2020Review
- Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System.Biomolecules · 2019Article
- Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes.American journal of physiology. Renal physiology · 2018Article
- Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.Kidney international · 2017Article
- Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease.PloS one · 2016Article
- Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013Article
- Regulation of urinary ACE2 in diabetic mice.American journal of physiology. Renal physiology · 2013Article
- Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor.Experimental physiology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin converting enzyme-2 (ACE2) is a recently described membrane-bound carboxypeptidase identified by its homology to ACE, the enzyme responsible for the formation of the potent vasoconstrictor angiotensin II (Ang II). ACE2 inactivates Ang II and is thus thought to act in a counter-regulatory fashion to ACE. ACE2 is highly expressed in epithelial cells of distal renal tubules, and recent evidence indicates that expression is increased in a range of renal diseases. A soluble form of ACE, generated by proteolytic cleavage of the membrane-bound form, has been shown to be present in urine; although evidence for a similar release of ACE2 has been reported in cell culture, it is not yet known whether this occurs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.